CN115572329B - Poecilobdella manillensis gene recombinant hirudin with slower activity enhancement metabolism and preparation method thereof - Google Patents
Poecilobdella manillensis gene recombinant hirudin with slower activity enhancement metabolism and preparation method thereof Download PDFInfo
- Publication number
- CN115572329B CN115572329B CN202110688404.4A CN202110688404A CN115572329B CN 115572329 B CN115572329 B CN 115572329B CN 202110688404 A CN202110688404 A CN 202110688404A CN 115572329 B CN115572329 B CN 115572329B
- Authority
- CN
- China
- Prior art keywords
- hirudin
- recombinant
- delta
- histag
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 title claims abstract description 79
- 108090000623 proteins and genes Proteins 0.000 title abstract description 72
- 230000000694 effects Effects 0.000 title abstract description 36
- 230000004060 metabolic process Effects 0.000 title abstract description 11
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 241000500851 Poecilobdella manillensis Species 0.000 title description 43
- 108010007267 Hirudins Proteins 0.000 claims abstract description 49
- 102000007625 Hirudins Human genes 0.000 claims abstract description 47
- 229940006607 hirudin Drugs 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 26
- 102000008300 Mutant Proteins Human genes 0.000 claims abstract description 17
- 108010021466 Mutant Proteins Proteins 0.000 claims abstract description 17
- 230000014509 gene expression Effects 0.000 claims description 31
- 150000001413 amino acids Chemical group 0.000 claims description 28
- 235000001014 amino acid Nutrition 0.000 claims description 27
- 229940024606 amino acid Drugs 0.000 claims description 27
- 239000013613 expression plasmid Substances 0.000 claims description 16
- 241000588724 Escherichia coli Species 0.000 claims description 13
- 238000000338 in vitro Methods 0.000 claims description 12
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 8
- 235000003704 aspartic acid Nutrition 0.000 claims description 8
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 3
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 46
- 230000010100 anticoagulation Effects 0.000 abstract description 18
- 210000004369 blood Anatomy 0.000 abstract description 13
- 239000008280 blood Substances 0.000 abstract description 13
- 238000003776 cleavage reaction Methods 0.000 abstract description 12
- 230000007017 scission Effects 0.000 abstract description 12
- 238000004458 analytical method Methods 0.000 abstract description 11
- 230000035772 mutation Effects 0.000 abstract description 7
- 102000004190 Enzymes Human genes 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- 206010064571 Gene mutation Diseases 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 5
- 230000000144 pharmacologic effect Effects 0.000 abstract description 5
- 108091005804 Peptidases Proteins 0.000 abstract description 3
- 239000004365 Protease Substances 0.000 abstract description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract description 2
- 238000012482 interaction analysis Methods 0.000 abstract 1
- 230000006916 protein interaction Effects 0.000 abstract 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 54
- 108090000190 Thrombin Proteins 0.000 description 42
- 235000018102 proteins Nutrition 0.000 description 37
- 229960004072 thrombin Drugs 0.000 description 35
- 239000013612 plasmid Substances 0.000 description 32
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 28
- 238000012163 sequencing technique Methods 0.000 description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
- 239000002773 nucleotide Substances 0.000 description 18
- 125000003729 nucleotide group Chemical group 0.000 description 18
- 210000002381 plasma Anatomy 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 16
- 230000001580 bacterial effect Effects 0.000 description 15
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 229910052759 nickel Inorganic materials 0.000 description 13
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 12
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 230000009465 prokaryotic expression Effects 0.000 description 11
- 108020004705 Codon Proteins 0.000 description 10
- 230000015271 coagulation Effects 0.000 description 10
- 238000005345 coagulation Methods 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- AECPDLSSUMDUAA-ZKWXMUAHSA-N Asn-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N AECPDLSSUMDUAA-ZKWXMUAHSA-N 0.000 description 9
- ZDJZEGYVKANKED-NRPADANISA-N Gln-Cys-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O ZDJZEGYVKANKED-NRPADANISA-N 0.000 description 9
- DUGYCMAIAKAQPB-GLLZPBPUSA-N Gln-Thr-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O DUGYCMAIAKAQPB-GLLZPBPUSA-N 0.000 description 9
- AUTNXSQEVVHSJK-YVNDNENWSA-N Glu-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O AUTNXSQEVVHSJK-YVNDNENWSA-N 0.000 description 9
- RPLLQZBOVIVGMX-QWRGUYRKSA-N Gly-Asp-Phe Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RPLLQZBOVIVGMX-QWRGUYRKSA-N 0.000 description 9
- BULIVUZUDBHKKZ-WDSKDSINSA-N Gly-Gln-Asn Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O BULIVUZUDBHKKZ-WDSKDSINSA-N 0.000 description 9
- XTQFHTHIAKKCTM-YFKPBYRVSA-N Gly-Glu-Gly Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O XTQFHTHIAKKCTM-YFKPBYRVSA-N 0.000 description 9
- HAPWZEVRQYGLSG-IUCAKERBSA-N His-Gly-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O HAPWZEVRQYGLSG-IUCAKERBSA-N 0.000 description 9
- BPMRXBZYPGYPJN-WHFBIAKZSA-N Ser-Gly-Asn Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O BPMRXBZYPGYPJN-WHFBIAKZSA-N 0.000 description 9
- 108091081024 Start codon Proteins 0.000 description 9
- NLJKZUGAIIRWJN-LKXGYXEUSA-N Thr-Asp-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N)O NLJKZUGAIIRWJN-LKXGYXEUSA-N 0.000 description 9
- ONNSECRQFSTMCC-XKBZYTNZSA-N Thr-Glu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ONNSECRQFSTMCC-XKBZYTNZSA-N 0.000 description 9
- YLRLHDFMMWDYTK-KKUMJFAQSA-N Tyr-Cys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLRLHDFMMWDYTK-KKUMJFAQSA-N 0.000 description 9
- LAYSXAOGWHKNED-XPUUQOCRSA-N Val-Gly-Ser Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LAYSXAOGWHKNED-XPUUQOCRSA-N 0.000 description 9
- HWNYVQMOLCYHEA-IHRRRGAJSA-N Val-Ser-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N HWNYVQMOLCYHEA-IHRRRGAJSA-N 0.000 description 9
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 9
- 108010016616 cysteinylglycine Proteins 0.000 description 9
- 108010045383 histidyl-glycyl-glutamic acid Proteins 0.000 description 9
- 230000014508 negative regulation of coagulation Effects 0.000 description 9
- 238000003259 recombinant expression Methods 0.000 description 9
- MYXNLWDWWOTERK-BHNWBGBOSA-N Gly-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN)O MYXNLWDWWOTERK-BHNWBGBOSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- SBHUBSDEZQFJHJ-CIUDSAMLSA-N Asp-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O SBHUBSDEZQFJHJ-CIUDSAMLSA-N 0.000 description 7
- YPMDZWPZFOZYFG-GUBZILKMSA-N Gln-Leu-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YPMDZWPZFOZYFG-GUBZILKMSA-N 0.000 description 7
- WLCYCADOWRMSAJ-CIUDSAMLSA-N Lys-Asn-Cys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(O)=O WLCYCADOWRMSAJ-CIUDSAMLSA-N 0.000 description 7
- LUTDBHBIHHREDC-IHRRRGAJSA-N Lys-Pro-Lys Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O LUTDBHBIHHREDC-IHRRRGAJSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- ILMLVTGTUJPQFP-FXQIFTODSA-N Pro-Asp-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ILMLVTGTUJPQFP-FXQIFTODSA-N 0.000 description 7
- 239000003593 chromogenic compound Substances 0.000 description 7
- 108010015792 glycyllysine Proteins 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- YDMBNDUHUNWWRP-VJBWXMMDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]piperidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C1=CC=CC=C1 YDMBNDUHUNWWRP-VJBWXMMDSA-N 0.000 description 6
- 102000003960 Ligases Human genes 0.000 description 6
- 108090000364 Ligases Proteins 0.000 description 6
- 108010039286 S 2238 Proteins 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 238000001261 affinity purification Methods 0.000 description 6
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 102220487444 Electron transfer flavoprotein subunit alpha, mitochondrial_L30I_mutation Human genes 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 230000002785 anti-thrombosis Effects 0.000 description 4
- 102220395130 c.128C>G Human genes 0.000 description 4
- 230000006957 competitive inhibition Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 102220576080 HLA class I histocompatibility antigen, B alpha chain_S48T_mutation Human genes 0.000 description 3
- 241000237903 Hirudo Species 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000012474 protein marker Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000007447 staining method Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- ITZWDGBYBPUZRG-KBIXCLLPSA-N Gln-Ile-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O ITZWDGBYBPUZRG-KBIXCLLPSA-N 0.000 description 2
- WJUYPBBCSSLVJE-CIUDSAMLSA-N His-Asn-Cys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N WJUYPBBCSSLVJE-CIUDSAMLSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- MSSABBQOBUZFKZ-IHRRRGAJSA-N Lys-Pro-His Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O MSSABBQOBUZFKZ-IHRRRGAJSA-N 0.000 description 2
- VJLJGKQAOQJXJG-CIUDSAMLSA-N Pro-Asp-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VJLJGKQAOQJXJG-CIUDSAMLSA-N 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 108010020688 glycylhistidine Proteins 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 229910001453 nickel ion Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002525 ultrasonication Methods 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- TZDNWXDLYFIFPT-BJDJZHNGSA-N Ala-Ile-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O TZDNWXDLYFIFPT-BJDJZHNGSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- HOBNTSHITVVNBN-ZPFDUUQYSA-N Asp-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N HOBNTSHITVVNBN-ZPFDUUQYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- ABPRMMYHROQBLY-NKWVEPMBSA-N Gly-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)CN)C(=O)O ABPRMMYHROQBLY-NKWVEPMBSA-N 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241001482592 Oreamnos americanus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 108010010967 hirudin HV1 Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 108010018006 histidylserine Proteins 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108010015680 recombinant human thrombin Proteins 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960003766 thrombin (human) Drugs 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Based on protein interaction analysis and pharmacological experiments by using a protein engineering principle and a method, the hirudin HM2-E60D-I62D with higher anticoagulation activity is prepared by the method. Based on analysis of enzyme cleavage sites of blood protease and artificial directed evolution random mutation, HM2-E60D-I62D mutant proteins with slower plasma metabolism speed are prepared by taking HM2-E60D-I62D as templates: HM2-E60D-I62D-K26H, HM2-E60D-I62D-L30I, HM2-E60D-I62D-K47H, HM2-E60D-I62D-S48T, HM2-E60D-I62D-K26H-L30I-K47H-S48T and HM2-E60D-I62D-T43S. The patent specification of the invention describes in detail the above hirudin gene mutation, the preparation method and the pharmacological effect thereof.
Description
Technical Field
The invention belongs to the field of protein engineering pharmacy, and in particular relates to a group of genetically modified hirudin with a primary structure, and a preparation method, a separation method and a purification method thereof.
Background
Hirudin (Hirudinaria manillensis) Hirudin (HM 2) is a polypeptide substance with anticoagulant activity secreted by the salivary glands of the blood-sucking Hirudin (Hirudin). HM2 is a single polypeptide chain consisting of 64 amino acids with a relative molecular mass of 6.8kD. In the clotting pathway, hirudin targets Thrombin, the core enzyme in the clotting cascade (Thrombin), which forms a stable, non-covalent complex with alpha-Thrombin in a stoichiometric 1:1 form, thereby blocking the ability of Thrombin to catalyze the formation of insoluble fibrin from fibrinogen. Analysis of the crystal structure of the hirudin-thrombin complex shows that the spherical N-terminal structure of hirudin binds to the hydrophobic active center of thrombin and that the C-terminal tail, which is rich in acidic amino acids, binds to the "Exosite I" of thrombin. "external site I" is the binding site of thrombin to fibrinogen. The combination mode of hirudin and thrombin is two-phase dynamic combination, and the C terminal seals the external site I of thrombin, so that the configuration of thrombin is slightly changed, and the combination of the N terminal and the active center of thrombin is promoted, thereby inhibiting the catalytic activity of thrombin. Various animal models and clinical pharmacological studies have shown that hirudin is effective in the prevention and treatment of thrombotic diseases, especially those in which thrombin plays a key role in pathogenesis.
Hirudin is mainly extracted from saliva of blood sucking leeches, and in recent years, researchers have expressed genetically recombinant hirudin by using microorganisms, but the C-terminal amino acid residue of the microorganism expressed hirudin is not sulfated, lacks a negatively charged group which interacts with "external site I", and thus has a lower anticoagulant activity than wild-type hirudin. In order to solve the problem, a plurality of amino acid residues at the C terminal are mutated into asparagi amino acid by utilizing a genetic engineering technology so as to increase the negative charge carried by the C terminal of hirudin, and thus, the gene recombinant hirudin with higher anticoagulation activity is obtained. Based on the mutant hirudin, a plurality of gene mutant hirudins are further constructed and expressed to delay the HM2 plasma metabolism speed, and the patent comprises the hirudin mutant which has been screened to have stronger activity than the wild hirudin and higher blood stability.
Disclosure of Invention
1. Object of the invention
A group of gene recombination amino acid mutant proteins are expressed and purified by using escherichia coli engineering strains, and the hirudin mutant has stronger anticoagulation activity and slower plasma metabolism and a preparation method thereof.
2. Technical scheme of the invention
1. Design of recombinant hirudin HM2 mutant for improving anticoagulant activity
Amino acid sequence alignment: the amino acid sequences of hirudin (HM 2, nucleotide or 1 st sequence in amino acid sequence table) and hirudin (HV 1) were obtained from Uniprot, and the amino acids of HM2 and HV1 were aligned using ClustalX2 software, with the key amino acid at the C-terminus of HM2 being aspartic acid at position 61 (FIG. 1).
Design of mutants: we designed and selected a number of mutants for increasing the anticoagulant activity of hirudin, described in this patent design are selected mutants HM2-D61A, HM2-E60D-I62D of HM 2.
2. Recombinant hirudin HM2 for improving anticoagulant activity and expression plasmid construction of mutant thereof
Preparing a template: CDS sequences for HM2 were obtained from NCBI. And (3) according to the preference of codons in the prokaryotic expression system, optimizing a base sequence (a nucleotide or an amino acid sequence table 2) and synthesizing.
Preparation of the sequence: PCR primers were designed, his affinity purification tags were introduced using the upstream primer, and the base sequences of amino acid mutation sites were introduced using the downstream primer sequence.
And (3) PCR amplification: mutation of aspartic acid (D) at position 61 of HM2 into alanine (A) (nucleotide or sequence 3 and 4 in the amino acid sequence table), simultaneous mutation of glutamic acid (E) at position 60 and isoleucine (I) at position 62 into aspartic acid (D) (nucleotide or sequence 5 and 6 in the amino acid sequence table), amplification of cDNA fragments with restriction enzyme sites (NdeI and HindIII) at both ends, ndeI-HisTag-HM2-HindIII, ndeI-HisTag-HM2-D61A-HindIII, ndeI-HisTag-HM2-E60D-I62D-HindIII, respectively, were obtained.
Restriction enzyme cleavage: the double digested DNA fragments NdeI-HisTag-HM2-HindIII, ndeI-HisTag-HM2-D61A-HindIII, ndeI-HisTag-HM2-E60D-I62D-HindIII, and vector pET21A (+), resulted in a cohesive end.
T4 ligase ligation: the viscous-terminated NdeI-HisTag-HM2-HindIII, ndeI-HisTag-HM2-D61A-HindIII, ndeI-HisTag-HM2-E60D-I62D-HindIII were ligated with the cut expression vector pET21A (+) using T4 ligase, respectively, to construct HM 2pET21A (+) with His affinity purification tag, HM2-D61A pET21A (+) and HM2-E60D-I62D pET21A (+) prokaryotic expression recombinant plasmids.
Identification of recombinant plasmids: the recombinant plasmid is transformed into escherichia coli DH5 alpha, and positive clones are subjected to double-enzyme digestion identification and DNA sequencing.
3. Prokaryotic expression of hirudin recombinant by Hirudinaria manillensis gene mutation for improving anticoagulant activity
Converting the successfully constructed recombinant plasmid into an escherichia coli expression strain BL21 (DE 3) by a heat shock method, and adding isopropyl-beta-d-thiogalactoside (IPTG) to induce the target protein to be expressed in a small amount; screening high expression strain and carrying out mass expression.
The cells expressing HM2 and HM2-D61A, HM2-E60D-I62D were disrupted by sonication, and the target protein expression was determined by Coomassie brilliant blue staining.
Separating and purifying HM2 and HM2-D61A, HM2-E60D-I62D proteins with His labels by utilizing a nickel ion affinity chromatography method and adopting a gradient concentration elution mode. After dialysis, the mixture is vacuumized and freeze-dried at 4 ℃ and stored at low temperature.
Sample protein concentrations were quantified using BCA. The protein samples after quantification are separated by SDS-PAGE (Bis-Tris gel), and purified proteins HM2 and HM2-D61A, HM2-E60D-I62D are detected by a Coomassie brilliant blue staining method, and the purified protein samples HM2 and HM2-D61A, HM2-E60D-I62D are identified by Western blot.
To avoid the lengthy names, particularly the various muteins constructed later on the basis of HM2-E60D-I62D, HM2-E60D-I62D is hereinafter denoted by HM 2.DELTA.60/62.
4. In vitro anticoagulation activity analysis of hirudin recombined by gene mutation of Poecilobdella manillensis
The binding capacity of hirudin to thrombin was analyzed by measuring the competitive inhibition constant Ki of recombinant hirudin to human alpha-thrombin. Ki was determined dynamically by enzymatic reaction using chromogenic substrate method. Wherein the chromogenic substrate is thrombin specific chromogenic substrate S-2238 (H-D-Phe-Pip-Arg-pNA.2HCl).
The in vitro anticoagulation activity of recombinant hirudin is analyzed by measuring the semi-inhibition constant IC50 of the recombinant hirudin to human alpha-thrombin by a chromogenic substrate method, and the thrombin specific substrate is S-2238.
The recombinant hirudin is incubated in vitro with healthy human plasma and the in vitro antithrombotic activity of the recombinant hirudin is further analyzed by measuring plasma coagulation indicators, including Activated Partial Thromboplastin Time (APTT), prothrombin Time (PT) and Thrombin Time (TT). The experimental results showed that HM 2.DELTA.60/62 was stronger in vitro anticoagulation than wild-type HM2 (FIGS. 10-13).
5. In vivo anticoagulation activity analysis of Hirudinaria manillensis gene mutation recombinant hirudin
The antithrombotic and anticoagulant activity of recombinant hirudin in vivo was analyzed by a gamma-carrageenan-induced mouse tail thrombus model. Recombinant hirudin was subcutaneously injected into Kunming mice for 5 days, gamma-carrageenan was intraperitoneally injected after the administration on day 3 to induce thrombosis in the tail of the mice, and thrombotic mice blood coagulation indexes APTT, PT and TT were detected after the continuous administration for 5 days to evaluate antithrombotic and anticoagulant effects of the recombinant hirudin. Experimental results showed that HM 2.DELTA.60/62 was stronger in anticoagulation in thrombus model mice than in wild-type HM2 (FIG. 14).
6. The presence of various proteases in the blood can degrade part of the hirudin, the degradation rate and the renal excretion rate affecting the concentration of hirudin in the plasma. We analyzed the cleavage sites of recombinant hirudin HM-2.DELTA.60/62 protein in human blood (excluding the N-terminal front 3 amino acid and the C-terminal 51-64 amino acids of HM-2.DELTA.60/62 protein) (Table 2), and based on the analysis results, introduced artificial directed evolution random mutation strategies to design and express various HM-2.DELTA.60/62 mutants, this patent includes HM-2.DELTA.60/62 mutant proteins K26H, L30I, K47H, S48T, K H-L30I-K47H-S48T and T43S, which have relatively remarkable effects.
7. Construction of Gene recombinant plasmid for retarding HM2Δ60/62 metabolism
The following takes the mutant protein HM2Δ60/62-K26H as an example, and the other five mutant proteins were constructed in the same way.
Preparation of a base sequence: the base sequence of the preferred amino acid mutein of E.coli was designed using the base sequence of HM 2.DELTA.60/62 as a template. cDNA architecture of HM2Δ60/62-K26H protein: ndeI-HisTag-HM2Δ60/62-K26H-HindIII and addition of restriction site protecting bases at both ends of the sequence.
Restriction enzyme cleavage: the recombinant plasmid K26H pUC57 and the expression vector pET21a (+) were digested with double enzymes to obtain a DNA fragment NdeI-HisTag-HM2Δ60/62-K26H-HindIII with a cohesive end and the vector pET21a (+).
T4 ligase ligation: the NdeI-HisTag-HM2Δ60/62-K26H-HindIII cut out of the cohesive ends and the vector pET21a (+) were ligated with T4 ligase, respectively, to construct a HisTag-HM2Δ60/62-K26H pET21a (+) prokaryotic expression recombinant plasmid.
Identification of recombinant plasmids: the recombinant plasmid is transformed into escherichia coli DH5 alpha, and positive clones are identified by double enzyme digestion and DNA sequencing.
The following His-tagged mutant HM2Δ60/62 was constructed using the same method: HM2Δ60/62-L30I pET21a (+), HM2Δ60/62-K47H pET21a (+), HM2Δ60/62-S48T pET21a (+), HM2Δ60/62-K26H-L30I-K47H-S48T pET21a (+), and HM2Δ60/62-T43S pET21a (+), and the recombinant plasmids. The expressed various HM2 delta 60/62 mutant proteins have the following sequence correspondence with the nucleotide or amino acid sequence list: HM2 delta 60/62-K26H corresponds to the 7 th and 8 th sequences; HM2 delta 60/62-L30I corresponds to sequence 9 and 10; HM2 delta 60/62-K47H corresponds to sequence 11 and 12; HM2 delta 60/62-S48T corresponds to sequences 13 and 14; HM2 delta 60/62-K26H-L30I-K47H-S48T corresponds to sequences 15 and 16; HM 2.DELTA.60/62-T43S corresponds to the 17 th and 18 th sequences.
8. Prokaryotic expression of muteins for delaying HM2Δ60/62 metabolism
Converting the successfully constructed recombinant plasmid into an escherichia coli expression strain BL21 (DE 3) by a heat shock method, and adding IPTG to induce the target protein to be expressed in a small amount; screening high expression strain and carrying out mass expression.
The expression thalli are crushed by an ultrasonic method, and the expression condition of the target protein is determined by a coomassie brilliant blue staining method. Separating and purifying HM2 delta 60/62 mutant proteins such as HM2 delta 60/62-K26H, HM delta 60/62-L30I, HM delta 60/62-K47H, HM delta 60/62-S48T, HM delta 60/62-K26H-L30I-K47H-S48T and HM2 delta 60/62-T43S by utilizing a nickel ion affinity chromatography method and adopting a gradient concentration elution mode. After dialysis, the mixture is vacuumized and freeze-dried at 4 ℃ and stored at low temperature.
Sample protein concentrations were quantified using BCA. The quantified protein samples are separated by SDS-PAGE (Bis-Tris gel), coomassie brilliant blue staining method is used for detecting HM2Delta60/62-K26H, HM Delta60/62-L30I, HM Delta60/62-K47H, HM Delta60/62-S48T, HM Delta60/62-K26H-L30I-K47H-S48T, HM2Delta60/62-T43S and other HM2Delta60/62 mutant proteins, and Western blot is used for qualitative identification of the purified proteins.
9. Antithrombin Activity assay for various HM2Δ60/62 muteins
In the above-described in vivo anticoagulation activity assay of the genetically modified hirudin, the in vitro IC50 concentration of HM2Δ60/62 was determined to be about 4.3nM (FIG. 12). In this section of the experiment, inhibition of thrombin activity by thrombin specific chromogenic substrates S-2238 (H-D-Phe-Pip-Arg-pNA.2HCl) was measured at final concentrations of 4.5nM HM2, HM 2.DELTA.60/62, HM.DELTA.60/62-K26H, HM 2.DELTA.60/62-L30I, HM 2.DELTA.60/62-K47H, HM 2.DELTA.60/62-S48. 48T, HM 2.DELTA.60/62-K26H-L30I-K47H-S48T and HM.DELTA.60/62-T43S. The experimental results showed that there was no significant difference between the inhibition levels of thrombin by various HM2Δ60/62 muteins and the effect was stronger than that of the genetically recombinant HM2 (FIG. 24).
10. Plasma concentration analysis 30 minutes after intravenous administration of various HM2Δ60/62 muteins
New Zealand white rabbits were given 50 μg/kg of HM2, HM 2.DELTA.60/62-K26H, HM 2.DELTA.60/62-L30I, HM 2.DELTA.60/62-K47H, HM 2.DELTA.60/62-S48T, HM 2.DELTA.60/62-K26H-L30I-K47H-S48T and HM 2.DELTA.60/62-T43S by intravenous injection for 30 minutes and were then collected blood, and the concentrations of the above hirudins in the plasma were determined by ELISA. The experimental results showed that the above HM2Δ60/62 mutant protein was relatively slow in metabolism in plasma (FIG. 25).
3. Advantageous effects of the invention
The invention can obtain a group of gene recombinant hirudin mutant proteins with higher anticoagulation activity and slower plasma metabolism, which are superior to wild or gene recombinant hirudin and have the advantages of short production period, low cost and the like.
Drawings
FIG. 1 amino acid sequence alignment of hirudin HV1, hirudin HM2 and hirudin gene mutant recombinant hirudin prepared in this patent. A: amino acid conservation is shown in grey with varying shades. B: the chemical nature of amino acids is indicated by grey with different shades (note: original image is colored). HM2Δ60/62: HM2-E60D-I62D.
FIG. 2 shows a map of the HisTag-HM 2pET21a (+) recombinant expression plasmid.
FIG. 3 shows a map of the recombinant expression plasmid of HisTag-HM2-D61A pET21A (+).
FIG. 4 shows a map of the recombinant expression plasmid of HisTag-HM2-E60D-I62D pET21a (+).
TABLE 1 general PCR primer sequences. The cleavage sites NdeI (AAGCTT) and HindIII (CATATG) are indicated by entities and underlined.
FIG. 5 shows the peak pattern of the sequencing result of the HisTag-HM 2pET21a (+) recombinant plasmid. The base sequence shown starts from the start codon ATG of the target gene, including the nucleotide sequence of the 5' -end encoding 6xHisTag, to three repeated TAA stop codons, and the sequencing result is correct.
FIG. 6 shows the peak diagram of the sequencing result of the HisTag-HM2-D61A pET21A (+) recombinant plasmid. The base sequence shown starts from the start codon ATG of the target gene, including the nucleotide sequence of the 5' -end encoding 6xHisTag, to three repeated TAA stop codons, and the sequencing result is correct.
FIG. 7 shows the peak pattern of the sequencing result of the HisTag-HM2-E60D-I62D pET21a (+) recombinant plasmid. The base sequence shown starts from the start codon ATG of the target gene, including the nucleotide sequence of the 5' -end encoding 6xHisTag, to three repeated TAA stop codons, and the sequencing result is correct.
FIG. 8 Coomassie brilliant blue staining pattern of recombinant expression plasmids HisTag-HM 2pET21A (+), hisTag-HM2-D61A pET21A (+), hisTag-HM2-E60D-I62D pET21A (+) expression products and products after nickel affinity purification. Panels A-C correspond in sequence to the results of the three recombinant plasmids above. After the recombinant expression plasmid is expressed in BL21 (DE 3) engineering bacteria, ultrasonic crushing is carried out, supernatant after centrifugation is purified by a nickel column, SDS-PAGE (Bis-tris) separation is carried out, and coomassie brilliant blue R-250 is dyed in situ. Wherein M is a pre-dye protein Marker (thermo Fisher,26616 or 26610); lane 1 is the uninduced bacterial body expression product; lane 2 is the induced bacterial body expression product; lane 3 is the supernatant solution after ultrasonic disruption of the induced cells; lane 4 is precipitation after induced cell sonication; lane 5 shows HM2 protein or HM2-D61A protein or HM2Δ60/62 protein after nickel affinity purification of the supernatant. The arrow indicates the destination strip.
FIG. 9 shows Western blot detection results of purified proteins HM2, HM2-D61A, HM2-E60D-I62D. After separation of HM2 and HM2-D61A, HM2-E60D-I62D proteins by SDS-PAGE (Bis-tris gel), transfer to NC membrane detection with low fluorescence background, primary antibody was anti-6 x HisTag mouse anti-monoclonal antibody, secondary antibody was goat anti-mouse IgG-Alexa Fluor 488, and finally fluorescence band was detected by Typhoon FLA 9500 (GE Healthcare). Wherein M is a pre-dye protein Marker (thermo Fisher, 26616); lanes 1-3 are purified proteins HM2, HM2-D61A, HM2-E60D-I62D, respectively. The arrow indicates the destination strip.
FIG. 10 measurement results of apparent Km of human alpha-thrombin by recombinant proteins HM2, HM2-D61A, HM2-E60D-I62D. The results show that: compared to Wild Type (WT) hirudin, HM2-D61A has a reduced affinity for thrombin, while HM2-E60D-I62D has an increased affinity for thrombin. Con: blank, WT: wild hirudin, HM2: gene recombinant hirudin, HM2-D61A: gene recombination HM2 Hirudo manillensis hirudin with aspartic acid at 61 position mutated into alanine, HM2-E60D-I62D: recombinant HM2 hirudin with glutamic acid at position 60 and isoleucine at position 62 mutated to aspartic acid.
FIG. 11 shows the results of measurement of the competitive inhibition constants Ki of recombinant proteins HM2, HM2-D61A, HM2-E60D-I62D for human alpha-thrombin. Wherein, the graphs A-D correspond to Wild Type (WT) hirudin, gene recombinant HM2 hirudin (HM 2), gene recombinant HM2 hirudin (HM 2-D61A) with aspartic acid at position 61 mutated to alanine, and gene recombinant HM2 hirudin (HM 2-E60D-I62D) with glutamic acid at position 60 and isoleucine at position 62 mutated to aspartic acid, respectively. The results show that the Ki value of HM2-D61A is 5 times that of HM2 and that of HM2-E60D-I62D is lower than that of WT.
FIG. 12 shows the results of measurement of the half-inhibition constant IC50 of the recombinant proteins HM2, HM2-D61A, HM 2.DELTA.60/62. WT: wild hirudin from Hirudo manillensis. The results showed that HM2-D61A was reduced in the ability to inhibit thrombin activity compared to the wild type; the inhibition capacity of HM2-E60D-I62D on thrombin activity is higher than that of wild hirudin. Activity: activity, concentration: concentration.
FIG. 13 effects of recombinant proteins HM2, HM2-D61A, HM2-E60D-I62D on blood plasma coagulation indicators APTT, PT and TT. Fig. A, B, C corresponds to the measurement results of the coagulation index APTT, PT, TT, respectively. The bar graph data are the mean ± SD, * P<0.05 or ** P<0.01, compared to wild-type hirudin (WT); # P<0.05 or ## P<0.01, compared to unmutated recombinant protein (HM 2); n=4. The results all showed that the coagulation index of the HM2-D61A group was significantly reduced compared to the wild-type WT group and the unmutated HM2 group; the coagulation index of the HM2-E60D-I62D group was significantly higher than that of the WT group.
FIG. 14 effects of recombinant proteins HM2, HM2-D61A, HM2-E60D-I62D on the coagulation indices APTT, PT and TT of thrombus model mice. Fig. A, B, C corresponds to the measurement results of the coagulation index APTT, PT, TT, respectively. Bar graph data are mean ± SD, ×p<0.05 or P<0.01, compared with wild hirudin (WT), # P<0.05 or ## P<0.01, n=12 compared to the genetically recombinant hirudin (HM 2). The results showed that HM2-D61A significantly decreased anticoagulant activity in mice compared to WT or HM2 group, while HM2-E60D-I62D had higher anticoagulant activity in mice.
Table 2. Results of analysis of the cleavage site of the HM2-E60D-I62D protein by blood protease. The black vertical bars represent possible cleavage sites.
FIG. 15 shows a map of the recombinant expression plasmid of HisTag-K26H pET21a (+). The red arc shows the open reading frame and transcription direction of the recombinant plasmid.
FIG. 16 shows the peak pattern of the sequencing result of the HisTag-HM2-E60D-I62D-K26H pET21a (+) recombinant plasmid. The sequencing peak shows the correct sequencing result starting from the start codon ATG of the target gene sequence, including the nucleotide sequence encoding 6xHisTag at the 5' end, to three repeated TAA stop codons.
FIG. 17 shows the peak pattern of the sequencing result of the HisTag-HM2-E60D-I62D-L30I pET21a (+) recombinant plasmid. The sequencing peak shows the correct sequencing result starting from the start codon ATG of the target gene sequence, including the nucleotide sequence encoding 6xHisTag at the 5' end, to three repeated TAA stop codons.
FIG. 18 shows the peak pattern of the sequencing result of HisTag-HM2-E60D-I62D-K47H pET21a (+) recombinant plasmid. The sequencing peak shows the correct sequencing result starting from the start codon ATG of the target gene sequence, including the nucleotide sequence encoding 6xHisTag at the 5' end, to three repeated TAA stop codons.
FIG. 19 is a peak diagram of the sequencing result of HisTag-HM2-E60D-I62D-S48T pET21a (+) recombinant plasmid. The sequencing peak shows the correct sequencing result starting from the start codon ATG of the target gene sequence, including the nucleotide sequence encoding 6xHisTag at the 5' end, to three repeated TAA stop codons.
FIG. 20 shows the peak diagram of the sequencing result of HisTag-HM2-E60D-I62D-K26H-L30I-K47H-S48T pET21a (+) recombinant plasmid. The sequencing peak shows the correct sequencing result starting from the start codon ATG of the target gene sequence, including the nucleotide sequence encoding 6xHisTag at the 5' end, to three repeated TAA stop codons.
FIG. 21 shows the peak pattern of the sequencing result of the HisTag-HM2-E60D-I62D-T43S pET21a (+) recombinant plasmid. The sequencing peak shows the correct sequencing result starting from the start codon ATG of the target gene sequence, including the nucleotide sequence encoding 6xHisTag at the 5' end, to three repeated TAA stop codons.
FIG. 22 shows Coomassie brilliant blue staining patterns of expression products and purification of HisTag-HM2-E60D-I62D pET21a (+) mutant recombinant plasmids such as K26H, L30I, K47H, S T, K H-L30I-K47H-S48T and T43S. Wherein, FIG. A, B, C, D, E, F is a Coomassie brilliant blue staining chart of recombinant plasmids HisTag-HM2-E60D-I62D-K26H pET21a (+), hisTag-HM2-E60D-I62D-L30I pET21a (+), hisTag-HM2-E60D-I62D-K47H pET21a (+), hisTag-HM2-E60D-I62D-S48T pET21a (+), hisTag-HM2-E60D-I62D-K26H-L30I-K47H-S48T pET21a (+), hisTag-HM2-E60D-I62D-T43S pET21a (+) and purified products, respectively. A. B, F, lane 1 is the uninduced bacterial body expression product; lane 2 is the induced bacterial body expression product; lane 3 is the induced bacterial body expression product supernatant; lane 4 is induced bacterial body expression product precipitation; lane 5 is the fraction of the supernatant after purification by nickel column. C. D, E, lane 1 is the uninduced bacterial body expression product; lane 2 is the induced bacterial body expression product; lane 3 is the induced bacterial body expression product supernatant; lane 4 is the fraction of the supernatant after purification by nickel column. M is a pre-dye protein Marker (ThermoFisher, 26616).
FIG. 23 shows Western blot detection results of purified HM2-E60D-I62D mutant proteins such as K26H, L30I, K H, S48T, K H-L30I-K47H-S48T and T43S. M: pre-dye protein molecular weight markers (thermo fisher, 26616); lane 1: purifying HM2-E60D-I62D-K26H protein; lane 2: purifying HM2-E60D-I62D-L30I protein; lanes: purifying HM2-E60D-I62D-K47H protein; lane 4: purifying HM2-E60D-I62D-S48T protein; lane 5: purifying HM2-E60D-I62D-K26H-L30I-K47H-S48T protein; lane 6: purifying HM2-E60D-I62D-T43S protein.
FIG. 24 inhibition of thrombin by various HM2-E60D-I62D muteins. HM2Δ60/62: HM2-E60D-I62D. Bar graph data are mean ± SE, P <0.01, n=6 compared to HM2 group.
FIG. 25 plasma concentrations of various HM2-E60D-I62D muteins after 30min intravenous injection. HM2Δ60/62: HM2-E60D-I62D. Bar graph data are mean ± SE, P <0.05 or P <0.01, n=4 compared to HM2 group.
Detailed description of the preferred embodiments
The first embodiment is as follows: in this embodiment, recombinant hirudin proteins HM2, HM2-D61A and HM2Δ60/62 are prokaryotic expressed and isolated and purified, and the steps are as follows:
1. recombinant hirudin HM2 for improving anticoagulation activity and expression plasmid construction of mutant thereof
The CDS sequence of HM2 was optimally designed according to codon preference in the prokaryotic expression system to be suitable for efficient expression in E.coli expression strain BL21 (DE 3). The PCR primer is designed to introduce amino acid mutation sites, and NdeI and HindIII are used as enzyme cutting sites at the upstream end and the downstream end of a recombinant protein CDS sequence, so that a prokaryotic expression sequence NdeI-HisTag-HM2HindIII, ndeI-HisTag-HM2-D61A-HindIII and NdeI-HisTag-HM2delta 60/62-HindIII with His tags are constructed. The method comprises the following specific steps:
primer design: the upstream primer F for amplifying HisTag-HM2 is designed: ndeI-HisTag-HM2-F (nucleotide or amino acid sequence No. 19 in the sequence Listing), downstream primer R: HM2-HindIII-R (nucleotide or amino acid sequence No. 20 in the sequence Listing); the upstream primer F for amplifying HisTag-HM2-D61A is designed: ndeI-HisTag-HM2-F, downstream primer R: D61A-HindIII-R (nucleotide or amino acid sequence of clause 21 of the sequence Listing); the upstream primer F for amplifying HisTag-HM2Δ60/62 was designed: ndeI-HisTag-HM2-F, downstream primer R: E60D-I62D-HindIII-R (nucleotide or amino acid sequence No. 22 of the sequence Listing) (Table 1).
Amplification of the target Gene: the target bands NdeI-HisTag-HM2-HindIII, ndeI-HisTag-HM2-D61A-HindIII, ndeI-HisTag-HM 2.DELTA.60/62-HindIII were amplified by a conventional PCR method using the artificially synthesized HM2 sequence as a template and primers F and R, respectively.
Restriction enzyme double enzyme digestion: double enzyme fragments with NdeI and HindIII, respectively
NdeI-HisTag-HM2-HindIII, ndeI-HisTag-HM2-D61A-HindIII, ndeI-HisTag-HM 2.DELTA.60/62-HindIII and empty vector pET21A (+).
T4 DNA ligase ligation: the target fragment and the vector were ligated with T4 DNA ligase to construct expression plasmids HisTag-HM 2pET21A (+), hisTag-HM2-D61A pET21A (+), hisTag-HM 2. DELTA.60/62 pET21A (+) (FIGS. 2 to 4).
Identification of recombinant plasmids: the constructed recombinant plasmid is transferred into escherichia coli, and the plasmid is extracted after amplification, and the sequencing result is correct (figures 5-7).
2. The prokaryotic expression of recombinant hirudin protein for improving the anticoagulation activity comprises the following specific steps:
induction of expression: transferring expression plasmids HisTag-HM 2pET21A (+), hisTag-HM2-D61A pET21A (+), hisTag-HM2 delta 60/62pET21A (+) into an E.coli expression strain BL21 (DE 3) at 42 ℃ for 45s, recovering the thallus for 1 hour at 37 ℃, and taking 50 mu L of the thallus for coatingThe culture was performed upside down on LB solid plates containing ampicillin at 37℃for 12 hours. Picking single colony into 10ml LB liquid medium containing ampicillin, shaking at 37deg.C and 180rpm for 12 hr, and culturing bacterial liquid at 1:50 to OD 600nm =0.6, and then IPTG was added at a final concentration of 1.0mM at 180rpm, at 25 ℃ for 9h of induction.
Affinity purification: the above-mentioned expression cells were collected in a centrifuge tube, centrifuged at 6,000rpm at 4℃for 15 minutes, and the supernatant was discarded. The cells were gently washed by adding non-denaturing lysate (50 mM Tris-HCl,300mM NaCl,10mM imidazole, pH 8.0), centrifuged at 12,000rpm at 4℃for 15min, and the pellet was collected and washed 3 times for 15min each. 8mL of non-denaturing lysate was added per gram wet weight and the cells were dispersed using a rotary mixer. The bacterial liquid is placed on ice, and the bacterial body is crushed by an ultrasonic crusher with the crushing power of 400W for 3s and the total crushing time of 5s is 200 times. Centrifugation was carried out at 12,000rpm at 4℃for 20min, the supernatant was collected and the recombinant hirudin protein was purified using a nickel column. The method comprises the following specific steps:
balance: 5 column volumes of 10mM imidazole buffer (50 mM NaH) 2 PO 4 The nickel column was equilibrated with 300mM NaCl,10mM imidazole). Loading: the supernatant after ultrasonication and centrifugation was applied to a nickel column and repeated 3 times. Rinsing: sequentially using 3 column volumes of 30mM imidazole buffer (50 mM NaH 2 PO 4 300mM NaCl, 30mM imidazole) and 3 column volumes of 50mM imidazole buffer (50 mM NaH) 2 PO 4 300mM NaCl, 50mM imidazole) to wash the nickel column to elute the poorly bound hybrid protein. Eluting: using 250mM imidazole buffer (50 mM NaH) 2 PO 4 300mM NaCl, 250mM imidazole), the eluted fractions were collected and the effluent of eluting the target protein per 1mL was stored in one EP tube.
Protein identification: the BCA method was used to determine the protein concentration of the sample. The quantitative sample protein was separated by SDS-PAGE (Bis-Tris gel), and the purification effect of the protein was analyzed by Coomassie brilliant blue staining (FIG. 8), and the molecular mass of the purified protein was identified by Western blot. Wherein, western blot transfers target protein to Nitrocellulose (NC) membrane by wet transfer (conditions: 200mA,100V,30 min), the primary antibody is anti-HisTag mouse anti-monoclonal antibody, and the secondary antibody is mountainGoat anti-mouse IgG H&L(Alexa488 Finally, the fluorescence band was detected with Typhoon FLA 9500 (GE Healthcare) (FIG. 9).
3. The in vitro and in vivo pharmacological experiments of the recombinant hirudin proteins HM2 and HM2-D61A, HM delta 60/62 for improving the anticoagulation activity are divided into two parts, namely in vitro anticoagulation activity measurement and in vivo anticoagulation activity analysis.
4. Measurement of in vitro anticoagulation activity of recombinant proteins HM2 and HM2-D61A, HM delta 60/62 comprises measurement of competitive inhibition constant Ki of recombinant proteins and human thrombin, measurement of half inhibition constant IC50 and measurement of blood plasma coagulation indexes APTT, PT and TT. The method comprises the following specific steps:
the Ki and IC50 assay was a chromogenic substrate method with a thrombin specific substrate of S-2238 (H-D-Phe-Pip-Arg-pNA.2HCl). The method comprises the following specific steps: control wells and sample wells were set, control wells were added with 40. Mu.L of sample diluent or 20. Mu.L of sample diluent and 20. Mu.L of human alpha-thrombin, and test sample wells were added with 20. Mu.L of test sample and 20. Mu.L of human alpha-thrombin. The reaction wells were sealed with tinfoil and incubated at room temperature for 10min. Subsequently, a chromogenic substrate S-2238160. Mu.L was added with a gun and carefully mixed, and immediately the absorbance values of each well at 405nm wavelength were dynamically measured every 10S interval for 10min using a microplate reader, and the apparent Km value (FIG. 10), competitive inhibition constant Ki value (FIG. 11) and half inhibition constant IC50 value (FIG. 12) were calculated from the absorbance change when the reaction was first order reaction.
The specific method for measuring the coagulation parameters of human plasma comprises the following steps: fresh frozen human plasma (Hainan Hospital, hemsleyakulare) was rapidly thawed in a 37℃water bath, and recombinant proteins HM2, HM2-D61A, HM. DELTA.60/62.5. Mu.g/ml were incubated with the thawed plasma at room temperature for 10min, respectively, and wild-type hirudin (WT) was used as a positive control group and physiological saline (NS) was used as a blank control group, and the coagulation index Activated Partial Thrombin Time (APTT), prothrombin Time (PT) and Thrombin Time (TT) were measured using a fully automatic hemagglutinator (CA-6500, sysmex) (FIG. 13).
5. Analysis of the antithrombotic Activity of recombinant proteins HM2, HM2-D61A, HM 2.DELTA.60/62 in vivo. The method comprises the following specific steps:
male Kunming mice (Liaoning Biotechnology Co., ltd.) of 20g weight at 4 weeks of age were selected and grouped into 5 groups, which were a Normal Saline (NS) blank control group, a wild type hirudin positive control group (WT) and three experimental groups, respectively: HM2, HM2-D61A, HM 2.DELTA.60/62. Mice in the administration group were subcutaneously injected with WT, HM2-D61A, HM. DELTA.60/62, drug concentration was 1mg/kg, and the blank group was injected with an equal volume of physiological saline for 5 consecutive days. After 30min on the third day of injection, mice of each group were intraperitoneally injected with 1% gamma carrageenan at a dose of 100mg/kg to induce thrombosis in the tail of the mice. After 30min of administration on the fifth day, the eyeballs were collected, plasma was separated, and blood coagulation indexes APTT, PT and TT of the collected plasma samples were detected by a blood coagulation instrument (CA-6500, sysmex) (FIGS. 14A, B, C).
6. The in-vitro and in-vivo pharmacological experiment results show that HM2 delta 60/62 is the hirudin with the Poecilobdella manillensis gene mutation recombinant hirudin with strong anticoagulation activity.
The second embodiment is as follows: in order to ensure higher stability of the recombinant protein HM2Δ60/62 in human blood in the first embodiment, the present embodiment analyzes the cleavage site of the recombinant hirudin protein HM2Δ60/62 in human blood (Table 2). Sequence analysis does not include the front 3 amino acids at the N-terminus and the 51-64 amino acids at the C-terminus of HM 2.DELTA.60/62. Based on the analysis result, an artificial directed evolution random mutation strategy is also introduced, and a plurality of HM2 delta 60/62 mutants are designed for analyzing the blood metabolism speed and the inhibition effect on thrombin.
7. Construction of Gene recombinant plasmid for improving blood stability of HM2Δ60/62
A variety of HM2Δ60/62 amino acid muteins are constructed which are not readily metabolized in blood, including K26H, L30I, K47H, S48T, K H-L30I-K47H-S48T and T43S. And constructing recombinant expression plasmids by adopting pET21a (+) as a prokaryotic expression vector. Taking the recombinant expression plasmid for constructing the K26H protein as an example (the other five mutant proteins are the same as the above), the steps are as follows:
preparation of a base sequence: the base sequence of the preferred amino acid mutant protein of Escherichia coli is designed by taking the base sequence of HM2delta 60/62 as a template, a protecting base, a cleavage site NdeI and a histidine tag (HisTag) and a cleavage site NdeI are sequentially added at the N end of the sequence, and a cleavage site HindIII and a protecting base are added at the C end of the sequence. The complete base sequence is submitted to complete gene synthesis by Shanghai worker.
Restriction enzyme cleavage: the recombinant plasmid K26H pUC57 and the expression vector pET21a (+) were digested with NdeI and HindIII to obtain a DNA fragment NdeI-HisTag-K26H-HindIII having cohesive ends and a digested pET21a (+) vector
T4 ligase ligation: the NdeI-HisTag-K26H-HindIII cut out the cohesive ends and the vector pET21a (+) were ligated with T4 ligase, respectively, to construct a HisTag-K26H pET21a (+) prokaryotic expression recombinant plasmid (FIG. 15).
Identification of recombinant expression plasmids: the recombinant plasmid was transformed into E.coli DH 5. Alpha. Strain by heat shock method (42 ℃ C., 45 s), coated with LB solid plate culture with ampicillin resistance, amplified, and sequenced with the plasmid, and the results are shown in FIGS. 16-21.
8. Prokaryotic expression of amino acid muteins is carried out as follows:
induction of expression: the expression plasmid was transferred into E.coli expression strain BL21 (DE 3) at 42℃for 45s, the cells were recovered at 37℃for 1 hour, 50. Mu.L of the recovered cells were plated on LB solid plates containing ampicillin, and the cells were cultured upside down at 37℃for 12 hours. Picking single colony to 10mL LB liquid medium with ampicillin, shaking at 37 ℃ and 180rpm for 12h, and transferring and culturing the bacterial liquid to OD according to the ratio of 1:50 600 =0.6, and then IPTG was added at a final concentration of 1.0mM at 180rpm, at 25 ℃ for 9h of induction.
Affinity purification: the above-mentioned expression cells were collected in a centrifuge tube, centrifuged at 6,000rpm at 4℃for 15 minutes, and the supernatant was discarded. The cells were gently washed by adding non-denaturing lysate (50 mM Tris-HCl,300mM NaCl,10mM imidazole, pH 8.0), centrifuged at 12,000rpm at 4℃for 15min, and the pellet was collected and washed 3 times for 15min each. 8mL of non-denaturing lysate was added per gram wet weight and the cells were dispersed using a rotary mixer. The bacterial liquid is placed on ice, and the bacterial body is crushed by an ultrasonic crusher with the crushing power of 400W for 3s and the total crushing time of 5s is 200 times. Centrifugation was carried out at 12,000rpm at 4℃for 20min, and the supernatant was collected and purified using nickel affinity chromatography. The method comprises the following specific steps:
balance: 5 column volumes of 10mM imidazole buffer (50 mM NaH) 2 PO 4 The nickel column was equilibrated with 300mM NaCl,10mM imidazole). Loading: the supernatant after ultrasonication and centrifugation was added to a nickel column and repeated 3 times. Rinsing: sequentially using 3 column volumes of 30mM imidazole buffer (50 mM NaH 2 PO 4 300mM NaCl, 30mM imidazole) and 3 column volumes of 50mM imidazole buffer (50 mM NaH) 2 PO 4 300mM NaCl, 50mM imidazole) to wash the nickel column to elute the poorly bound hybrid protein. Eluting: using 250mM imidazole buffer (50 mM NaH 2 PO 4 300mM NaCl, 250mM imidazole), the eluted fractions were collected and the effluent of eluting the target protein per 1mL was stored in one EP tube.
Protein identification: the BCA method was used to determine the protein concentration of the sample. The quantified sample proteins were separated by SDS-PAGE (Bis-Tris gel), and the protein purification effect was analyzed by Coomassie blue staining (FIG. 22), and the purified proteins were identified by Western blot (FIG. 23). Wherein, western blot transfers target protein to nitrocellulose membrane by wet transfer (conditions: 200mA,100V,30 min), the primary antibody is anti-6 xHisTag mouse anti-monoclonal antibody, and the secondary antibody is goat anti-mouse IgG H&L(Alexa488 Finally, the fluorescence band was detected with Typhoon FLA 9500 (GE Healthcare).
9. Inhibition of thrombin assay for various HM2Δ60/62 muteins, the specific procedure is as follows:
in the previous in vivo anticoagulation activity assay of the genetically modified hirudin, it has been determined that the in vitro IC50 concentration of HM2Δ60/62 is about 4.3nM (FIG. 12). In this section of the experiment, inhibition of thrombin activity by thrombin specific chromogenic substrates S-2238 (H-D-Phe-Pip-Arg-pNA.2HCl) was measured at final concentrations of 4.5nM HM2, HM 2.DELTA.60/62, HM.DELTA.60/62-K26H, HM 2.DELTA.60/62-L30I, HM 2.DELTA.60/62-K47H, HM 2.DELTA.60/62-S48. 48T, HM 2.DELTA.60/62-K26H-L30I-K47H-S48T and HM.DELTA.60/62-T43S. The method comprises the following specific steps: 20. Mu.L of each HM 2.DELTA.60/62 mutein (final concentration 4.5 nM) was incubated with 20. Mu.L of alpha-thrombin at room temperature for 10min, and after adding 160. Mu.L of thrombin-specific substrate S-2238 (H-D-Phe-Pip-Arg-pNA.2 HCl) solution for 10min, the p-nitroaniline level was measured at 405nM, which revealed that there was no significant difference between the effects of each HM 2.DELTA.60/62 mutein on inhibition of thrombin and that the thrombin-inhibiting activity was stronger than HM2 (FIG. 24).
10. Metabolic stability analysis of various HM 2.DELTA.60/62 muteins was performed as follows:
male New Zealand white rabbits weighing about 2.4kg were randomly divided into 7 groups of 4 animals each. The ear vein was injected with 50. Mu.g/kg of the following hirudins: HM2, HM2 delta 60/62-K26H, HM delta 60/62-L30I, HM delta 60/62-K47H, HM delta 60/62-S48T, HM delta 60/62-K26H-L30I-K47H-S48T and HM2 delta 60/62-T43S. After 30 minutes of drug injection, the ear margin was collected by intravenous blood, anticoagulated with 3.8% sodium citrate (9:1), centrifuged at 3000rpm for 10 minutes, and plasma was collected and assayed for various hirudin concentrations by polyclonal antibody ELISA, which showed that the above various HM2Δ60/62 muteins had a lower plasma clearance rate than HM2 and HM2Δ60/62, which was slower (FIG. 25).
Sequence listing
<110> Wang Dayong
<120> a group of Hirudo manillensis gene recombinant hirudin with slower activity enhancing metabolism and preparation method thereof
<130> 20210618
<141> 2021-06-18
<160> 22
<170> SIPOSequenceListing 1.0
<210> 1
<211> 64
<212> PRT
<213> Poecilobdella manillensis (Hirudinaria manillensis)
<400> 1
Val Ser Tyr Thr Asp Cys Thr Glu Ser Gly Gln Asn Tyr Cys Leu Cys
1 5 10 15
Val Gly Ser Asn Val Cys Gly Glu Gly Lys Asn Cys Gln Leu Ser Ser
20 25 30
Ser Gly Asn Gln Cys Val His Gly Glu Gly Thr Pro Lys Pro Lys Ser
35 40 45
Gln Thr Glu Gly Asp Phe Glu Glu Ile Pro Asp Glu Asp Ile Leu Asn
50 55 60
<210> 2
<211> 192
<212> DNA
<213> Poecilobdella manillensis (Hirudinaria manillensis)
<400> 2
gtttcttaca ccgactgcac cgaatctggt cagaactact gcctgtgcgt tggttctaac 60
gtttgcggtg aaggtaaaaa ctgccagctg tcttcttctg gtaaccagtg cgttcacggt 120
gaaggtaccc cgaaaccgaa atctcagacc gaaggtgact tcgaagaaat cccggacgaa 180
gacatcctga ac 192
<210> 3
<211> 64
<212> PRT
<213> Poecilobdella manillensis (Hirudinaria manillensis)
<400> 3
Val Ser Tyr Thr Asp Cys Thr Glu Ser Gly Gln Asn Tyr Cys Leu Cys
1 5 10 15
Val Gly Ser Asn Val Cys Gly Glu Gly Lys Asn Cys Gln Leu Ser Ser
20 25 30
Ser Gly Asn Gln Cys Val His Gly Glu Gly Thr Pro Lys Pro Lys Ser
35 40 45
Gln Thr Glu Gly Asp Phe Glu Glu Ile Pro Asp Glu Ala Ile Leu Asn
50 55 60
<210> 4
<211> 192
<212> DNA
<213> Poecilobdella manillensis (Hirudinaria manillensis)
<400> 4
gtttcttaca ccgactgcac cgaatctggt cagaactact gcctgtgcgt tggttctaac 60
gtttgcggtg aaggtaaaaa ctgccagctg tcttcttctg gtaaccagtg cgttcacggt 120
gaaggtaccc cgaaaccgaa atctcagacc gaaggtgact tcgaagaaat cccggacgaa 180
gcgatcctga ac 192
<210> 5
<211> 64
<212> PRT
<213> Poecilobdella manillensis (Hirudinaria manillensis)
<400> 5
Val Ser Tyr Thr Asp Cys Thr Glu Ser Gly Gln Asn Tyr Cys Leu Cys
1 5 10 15
Val Gly Ser Asn Val Cys Gly Glu Gly Lys Asn Cys Gln Leu Ser Ser
20 25 30
Ser Gly Asn Gln Cys Val His Gly Glu Gly Thr Pro Lys Pro Lys Ser
35 40 45
Gln Thr Glu Gly Asp Phe Glu Glu Ile Pro Asp Asp Asp Asp Leu Asn
50 55 60
<210> 6
<211> 192
<212> DNA
<213> Poecilobdella manillensis (Hirudinaria manillensis)
<400> 6
gtttcttaca ccgactgcac cgaatctggt cagaactact gcctgtgcgt tggttctaac 60
gtttgcggtg aaggtaaaaa ctgccagctg tcttcttctg gtaaccagtg cgttcacggt 120
gaaggtaccc cgaaaccgaa atctcagacc gaaggtgact tcgaagaaat cccggacgac 180
gacgacctga ac 192
<210> 7
<211> 64
<212> PRT
<213> Poecilobdella manillensis (Hirudinaria manillensis)
<400> 7
Val Ser Tyr Thr Asp Cys Thr Glu Ser Gly Gln Asn Tyr Cys Leu Cys
1 5 10 15
Val Gly Ser Asn Val Cys Gly Glu Gly His Asn Cys Gln Leu Ser Ser
20 25 30
Ser Gly Asn Gln Cys Val His Gly Glu Gly Thr Pro Lys Pro Lys Ser
35 40 45
Gln Thr Glu Gly Asp Phe Glu Glu Ile Pro Asp Asp Asp Asp Leu Asn
50 55 60
<210> 8
<211> 192
<212> DNA
<213> Poecilobdella manillensis (Hirudinaria manillensis)
<400> 8
gtttcttaca ccgactgcac cgaatctggt cagaactact gcctgtgcgt tggttctaac 60
gtttgcggtg aaggtcacaa ctgccagctg tcttcttctg gtaaccagtg cgttcacggt 120
gaaggtaccc cgaaaccgaa atctcagacc gaaggtgact tcgaagaaat cccggacgac 180
gacgacctga ac 192
<210> 9
<211> 64
<212> PRT
<213> Poecilobdella manillensis (Hirudinaria manillensis)
<400> 9
Val Ser Tyr Thr Asp Cys Thr Glu Ser Gly Gln Asn Tyr Cys Leu Cys
1 5 10 15
Val Gly Ser Asn Val Cys Gly Glu Gly Lys Asn Cys Gln Ile Ser Ser
20 25 30
Ser Gly Asn Gln Cys Val His Gly Glu Gly Thr Pro Lys Pro Lys Ser
35 40 45
Gln Thr Glu Gly Asp Phe Glu Glu Ile Pro Asp Asp Asp Asp Leu Asn
50 55 60
<210> 10
<211> 192
<212> DNA
<213> Poecilobdella manillensis (Hirudinaria manillensis)
<400> 10
gtttcttaca ccgactgcac cgaatctggt cagaactact gcctgtgcgt tggttctaac 60
gtttgcggtg aaggtaaaaa ctgccagatc tcttcttctg gtaaccagtg cgttcacggt 120
gaaggtaccc cgaaaccgaa atctcagacc gaaggtgact tcgaagaaat cccggacgac 180
gacgacctga ac 192
<210> 11
<211> 64
<212> PRT
<213> Poecilobdella manillensis (Hirudinaria manillensis)
<400> 11
Val Ser Tyr Thr Asp Cys Thr Glu Ser Gly Gln Asn Tyr Cys Leu Cys
1 5 10 15
Val Gly Ser Asn Val Cys Gly Glu Gly Lys Asn Cys Gln Leu Ser Ser
20 25 30
Ser Gly Asn Gln Cys Val His Gly Glu Gly Thr Pro Lys Pro His Ser
35 40 45
Gln Thr Glu Gly Asp Phe Glu Glu Ile Pro Asp Asp Asp Asp Leu Asn
50 55 60
<210> 12
<211> 192
<212> DNA
<213> Poecilobdella manillensis (Hirudinaria manillensis)
<400> 12
gtttcttaca ccgactgcac cgaatctggt cagaactact gcctgtgcgt tggttctaac 60
gtttgcggtg aaggtaaaaa ctgccagctg tcttcttctg gtaaccagtg cgttcacggt 120
gaaggtaccc cgaaaccgca ctctcagacc gaaggtgact tcgaagaaat cccggacgac 180
gacgacctga ac 192
<210> 13
<211> 64
<212> PRT
<213> Poecilobdella manillensis (Hirudinaria manillensis)
<400> 13
Val Ser Tyr Thr Asp Cys Thr Glu Ser Gly Gln Asn Tyr Cys Leu Cys
1 5 10 15
Val Gly Ser Asn Val Cys Gly Glu Gly Lys Asn Cys Gln Leu Ser Ser
20 25 30
Ser Gly Asn Gln Cys Val His Gly Glu Gly Thr Pro Lys Pro Lys Thr
35 40 45
Gln Thr Glu Gly Asp Phe Glu Glu Ile Pro Asp Asp Asp Asp Leu Asn
50 55 60
<210> 14
<211> 192
<212> DNA
<213> Poecilobdella manillensis (Hirudinaria manillensis)
<400> 14
gtttcttaca ccgactgcac cgaatctggt cagaactact gcctgtgcgt tggttctaac 60
gtttgcggtg aaggtaaaaa ctgccagctg tcttcttctg gtaaccagtg cgttcacggt 120
gaaggtaccc cgaaaccgaa aacccagacc gaaggtgact tcgaagaaat cccggacgac 180
gacgacctga ac 192
<210> 15
<211> 64
<212> PRT
<213> Poecilobdella manillensis (Hirudinaria manillensis)
<400> 15
Val Ser Tyr Thr Asp Cys Thr Glu Ser Gly Gln Asn Tyr Cys Leu Cys
1 5 10 15
Val Gly Ser Asn Val Cys Gly Glu Gly His Asn Cys Gln Ile Ser Ser
20 25 30
Ser Gly Asn Gln Cys Val His Gly Glu Gly Thr Pro Lys Pro His Thr
35 40 45
Gln Thr Glu Gly Asp Phe Glu Glu Ile Pro Asp Asp Asp Asp Leu Asn
50 55 60
<210> 16
<211> 192
<212> DNA
<213> Poecilobdella manillensis (Hirudinaria manillensis)
<400> 16
gtttcttaca ccgactgcac cgaatctggt cagaactact gcctgtgcgt tggttctaac 60
gtttgcggtg aaggtcacaa ctgccagatc tcttcttctg gtaaccagtg cgttcacggt 120
gaaggtaccc cgaaaccgca cacccagacc gaaggtgact tcgaagaaat cccggacgac 180
gacgacctga ac 192
<210> 17
<211> 64
<212> PRT
<213> Poecilobdella manillensis (Hirudinaria manillensis)
<400> 17
Val Ser Tyr Thr Asp Cys Thr Glu Ser Gly Gln Asn Tyr Cys Leu Cys
1 5 10 15
Val Gly Ser Asn Val Cys Gly Glu Gly Lys Asn Cys Gln Leu Ser Ser
20 25 30
Ser Gly Asn Gln Cys Val His Gly Glu Gly Ser Pro Lys Pro Lys Ser
35 40 45
Gln Thr Glu Gly Asp Phe Glu Glu Ile Pro Asp Asp Asp Asp Leu Asn
50 55 60
<210> 18
<211> 192
<212> DNA
<213> Poecilobdella manillensis (Hirudinaria manillensis)
<400> 18
gtttcttaca ccgactgcac cgaatctggt cagaactact gcctgtgcgt tggttctaac 60
gtttgcggtg aaggtaaaaa ctgccagctg tcttcttctg gtaaccagtg cgttcacggt 120
gaaggttctc cgaaaccgaa atctcagacc gaaggtgact tcgaagaaat cccggacgac 180
gacgacctga ac 192
<210> 19
<211> 37
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 19
attccatatg caccaccacc accaccacgt ttcttac 37
<210> 20
<211> 36
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 20
cccaagcttt tattattagt tcaggatgtc ttcgtc 36
<210> 21
<211> 34
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 21
cccaagcttt tattattagt tcaggatcgc ttcg 34
<210> 22
<211> 38
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 22
cccaagcttt tattattagt tcaggtcgtc gtcgtccg 38
Claims (3)
1. The hirudin gene recombinant mutant protein HM2-E60D-I62D is characterized in that the amino acid sequence is shown as SEQ ID NO:1 by simultaneously mutating glutamic acid at position 60 and isoleucine at position 62 thereof to aspartic acid.
2. The recombinant mutant protein prepared based on the hirudin recombinant mutant protein HM2-E60D-I62D according to claim 1, wherein the amino acid sequence HM2-E60D-I62D is used as a template, the 26 th amino acid, the 30 th amino acid, the 43 rd amino acid, the 47 th amino acid and the 48 th amino acid are mutated, or the 26 th amino acid, the 30 th amino acid, the 47 th amino acid and the 48 th amino acid are mutated simultaneously to obtain the HM2-E60D-I62D mutant protein: HM2-E60D-I62D-K26H, HM2-E60D-I62D-L30I, HM2-E60D-I62D-K47H, HM2-E60D-I62D-S48T, HM2-E60D-I62D-T43S or HM2-E60D-I62D-K26H-L30I-K47H-S48T.
3. An in vitro expression method of the recombinant mutein of claim 1 or claim 2, characterized in that the expression is performed in e.coli using an inducible expression plasmid;
the inducible expression plasmid is pET21a (+); the escherichia coli is escherichia coli expression strain BL21 (DE 3).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110688404.4A CN115572329B (en) | 2021-06-21 | 2021-06-21 | Poecilobdella manillensis gene recombinant hirudin with slower activity enhancement metabolism and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110688404.4A CN115572329B (en) | 2021-06-21 | 2021-06-21 | Poecilobdella manillensis gene recombinant hirudin with slower activity enhancement metabolism and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115572329A CN115572329A (en) | 2023-01-06 |
| CN115572329B true CN115572329B (en) | 2024-02-06 |
Family
ID=84579849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110688404.4A Active CN115572329B (en) | 2021-06-21 | 2021-06-21 | Poecilobdella manillensis gene recombinant hirudin with slower activity enhancement metabolism and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115572329B (en) |
Citations (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991017250A1 (en) * | 1990-05-10 | 1991-11-14 | Farmitalia Carlo Erba S.R.L. | Method for the recombinant production of hiridius and hirudin-like polypeptides |
| EP0511393A1 (en) * | 1990-11-08 | 1992-11-04 | Japan Energy Corporation | Hirudine mutant, production thereof, anticoagulant, secretory vector, microorganism transformed by said vector, and production of product from said microorganism |
| CN1066272A (en) * | 1991-02-28 | 1992-11-18 | 法米塔利亚·卡洛·埃巴有限责任公司 | The preparation method of anti-thrombin polypeptides |
| US5166318A (en) * | 1989-06-09 | 1992-11-24 | Mitsui Toatsu Chemicals, Incorporated | Polypeptide having thrombin inhibiting activity |
| WO1993000363A1 (en) * | 1991-06-27 | 1993-01-07 | Farmitalia Carlo Erba S.R.L. | Anti-hirudin polyclonal antibodies and their use for the identification, immunopurification and quantitative determination of hirudin |
| WO1995003409A1 (en) * | 1993-07-22 | 1995-02-02 | Ministero Dell' Universita' E Della Ricerca Scientifica E Tecnologica | Analogues of an anti-thrombin polypeptide and process for their preparation |
| US5472942A (en) * | 1988-11-11 | 1995-12-05 | Biopharm (Uk) Limited | Anti-thrombins |
| US5919895A (en) * | 1990-03-22 | 1999-07-06 | Consortium Fur Elektrochemische Industrie Gmbh | Secretion of hirudin derivatives |
| US5972648A (en) * | 1993-09-28 | 1999-10-26 | Japan Energy Corporation | Hirudin analogs, methods of manufacture thereof and anticoagulant compositions having these as active ingredients |
| CN1374970A (en) * | 1999-09-18 | 2002-10-16 | 阿文蒂斯药物德国有限公司 | Signal sequence for the productino of leu-hirudine via secretion by E coli in a culture medium |
| US6514730B1 (en) * | 1991-03-21 | 2003-02-04 | Consortium für elektrochemische Industrie GmbH | Secretion of hirudin derivatives |
| CN1536082A (en) * | 2003-04-07 | 2004-10-13 | 北京大学 | Coding gene of hirudin mutant and high-effective expression strain |
| WO2008071081A1 (en) * | 2006-12-15 | 2008-06-19 | Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla | Preparation of low bleeding anticoagulant fusion protein and its use |
| CN102153646A (en) * | 2010-12-31 | 2011-08-17 | 中国药科大学 | Optimal design and application of novel double-action target spot recombinant hirudin mutant |
| CN102574909A (en) * | 2009-05-05 | 2012-07-11 | 自然环境研究会 | Method of modifying serine protease inhibitors |
| CN103059130A (en) * | 2012-12-22 | 2013-04-24 | 浙江工业大学 | Hirudin mutant and genetically engineered bacterium thereof |
| CN103848914A (en) * | 2012-11-29 | 2014-06-11 | 河北以岭医药研究院有限公司 | Bufrudin polypeptide with anticoagulant activity and preparation method and purpose thereof |
| CN107098964A (en) * | 2017-05-19 | 2017-08-29 | 何向锋 | A kind of tumour-specific lepirudin 023 ludon and its production and use |
| CN109824772A (en) * | 2019-02-28 | 2019-05-31 | 海南大学 | The gene recombinant human corticotropin(ACTH) precursor and preparation method of one group of raising serum glucocorticoid level |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004076484A1 (en) * | 2003-02-27 | 2004-09-10 | National Research Council Of Canada | Peptide inhibitors of thrombin as potent anticoagulants |
-
2021
- 2021-06-21 CN CN202110688404.4A patent/CN115572329B/en active Active
Patent Citations (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5472942A (en) * | 1988-11-11 | 1995-12-05 | Biopharm (Uk) Limited | Anti-thrombins |
| US5166318A (en) * | 1989-06-09 | 1992-11-24 | Mitsui Toatsu Chemicals, Incorporated | Polypeptide having thrombin inhibiting activity |
| US5919895A (en) * | 1990-03-22 | 1999-07-06 | Consortium Fur Elektrochemische Industrie Gmbh | Secretion of hirudin derivatives |
| WO1991017250A1 (en) * | 1990-05-10 | 1991-11-14 | Farmitalia Carlo Erba S.R.L. | Method for the recombinant production of hiridius and hirudin-like polypeptides |
| EP0511393A1 (en) * | 1990-11-08 | 1992-11-04 | Japan Energy Corporation | Hirudine mutant, production thereof, anticoagulant, secretory vector, microorganism transformed by said vector, and production of product from said microorganism |
| CN1066272A (en) * | 1991-02-28 | 1992-11-18 | 法米塔利亚·卡洛·埃巴有限责任公司 | The preparation method of anti-thrombin polypeptides |
| US5356875A (en) * | 1991-02-28 | 1994-10-18 | Farmitalia Carlo Erba S.R.L. | Anti-thrombin polypeptides and pharmaceutical compositions thereof |
| US6514730B1 (en) * | 1991-03-21 | 2003-02-04 | Consortium für elektrochemische Industrie GmbH | Secretion of hirudin derivatives |
| WO1993000363A1 (en) * | 1991-06-27 | 1993-01-07 | Farmitalia Carlo Erba S.R.L. | Anti-hirudin polyclonal antibodies and their use for the identification, immunopurification and quantitative determination of hirudin |
| WO1995003409A1 (en) * | 1993-07-22 | 1995-02-02 | Ministero Dell' Universita' E Della Ricerca Scientifica E Tecnologica | Analogues of an anti-thrombin polypeptide and process for their preparation |
| US5972648A (en) * | 1993-09-28 | 1999-10-26 | Japan Energy Corporation | Hirudin analogs, methods of manufacture thereof and anticoagulant compositions having these as active ingredients |
| CN1374970A (en) * | 1999-09-18 | 2002-10-16 | 阿文蒂斯药物德国有限公司 | Signal sequence for the productino of leu-hirudine via secretion by E coli in a culture medium |
| CN1550502A (en) * | 1999-09-18 | 2004-12-01 | ���ĵ�˹ҩ��¹�����˾ | Signal sequences for the production of Leu-hirudine via secretion by E. coli in a culture medium |
| CN1536082A (en) * | 2003-04-07 | 2004-10-13 | 北京大学 | Coding gene of hirudin mutant and high-effective expression strain |
| WO2008071081A1 (en) * | 2006-12-15 | 2008-06-19 | Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla | Preparation of low bleeding anticoagulant fusion protein and its use |
| CN102574909A (en) * | 2009-05-05 | 2012-07-11 | 自然环境研究会 | Method of modifying serine protease inhibitors |
| CN102153646A (en) * | 2010-12-31 | 2011-08-17 | 中国药科大学 | Optimal design and application of novel double-action target spot recombinant hirudin mutant |
| CN103848914A (en) * | 2012-11-29 | 2014-06-11 | 河北以岭医药研究院有限公司 | Bufrudin polypeptide with anticoagulant activity and preparation method and purpose thereof |
| CN103059130A (en) * | 2012-12-22 | 2013-04-24 | 浙江工业大学 | Hirudin mutant and genetically engineered bacterium thereof |
| CN107098964A (en) * | 2017-05-19 | 2017-08-29 | 何向锋 | A kind of tumour-specific lepirudin 023 ludon and its production and use |
| CN109824772A (en) * | 2019-02-28 | 2019-05-31 | 海南大学 | The gene recombinant human corticotropin(ACTH) precursor and preparation method of one group of raising serum glucocorticoid level |
Non-Patent Citations (11)
| Title |
|---|
| A53883: hirudin HV1 homolog bufrudin - leech (Hirudinaria manillensis);GenBank;《GenBank》;标题、PROTEIN、CDS、ORIGIN部分 * |
| AltName: Full=Bufrudin ; AltName: Full=Hirudin-HV1 ; Flags: Precursor.《GenBank》.2021,标题、PROTEIN、CDS、ORIGIN部分. * |
| APA20848.1: hirudin variant HM4, partial [Hirudinaria manillensis];GenBank;《GenBank》;标题、PROTEIN、CDS、ORIGIN部分 * |
| GenBank.P81492.2: RecName: Full=Hirudin-HM2 * |
| NMR solution structure of a novel hirudin variant HM2, N-terminal 1-47 and N64-->V + G mutant;Giuseppe Nicastro等;《Biopolymers》;第41卷(第07期);第731-749页 * |
| Novel hirudin variants from the leech Hirudinaria manillensis. Amino acid sequence, cDNA cloning and genomic organization;Emanuela SCACHERI等;《European Journal of Biochemistry》;第214卷(第01期);第295-304页 * |
| The effects of overexpression of cytoplasmic chaperones on secretory production of hirudin-PA in E-coli;Nafiseh Alsadat Seyed Hosseini Fin等;《Protein Expression and Purification》;第157卷;第42-49页 * |
| 分泌型水蛭素Ⅱ基因工程菌的构建;林陈水、陈微微;《浙江工业大学学报》;第42卷(第01期);第50-53页 * |
| 广西菲牛蛭水蛭素基因cDNA的克隆与序列分析;黎渊弘;《中国生化药物杂志》;第32卷(第02期);第92-98页 * |
| 水蛭抗凝血活性物质提取方法研究;杨思毅等;《山东化工》;第45卷(第05期);第42-44页 * |
| 重组水蛭素Ⅲ分子改建及其构效关系的初步研究;谭树华等;《中国生物工程杂志》;第23卷(第08期);第69-73页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115572329A (en) | 2023-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Neeper et al. | Characterization of recombinant tick anticoagulant peptide. A highly selective inhibitor of blood coagulation factor Xa. | |
| AU633832B2 (en) | Novel antimicrobial peptide, compositions containing same and uses thereof | |
| KR100316347B1 (en) | Recombinant microorganisms expressing a fusion protein of Escherichia coli enterotoxin II signal peptide and fusion protein of human growth hormone and a method of producing human growth hormone using the same | |
| JPH0687778B2 (en) | Human antithrombin III | |
| Tan et al. | Efficient expression and secretion of recombinant hirudin III in E. coli using the L-asparaginase II signal sequence | |
| EP0687731B1 (en) | Secretion vector, transformed microorganisms containing said vector and manufacture of products from said microorganism | |
| CA2025070C (en) | Recombinant aprotinin variants genetically engineered process for the microbial preparation of homgeneously processed aprotinin variants and the therapeutic use thereof | |
| JPH04503761A (en) | PAI-2 mutants | |
| WO1998005786A2 (en) | Afc1 and rce1:isoprenylated caax processing enzymes | |
| JP3011274B2 (en) | Recombinantly produced 3-des-hydroxy-cystatin C polypeptide or modified product thereof | |
| RU2186110C2 (en) | Recombinant protein asp-pallidipin, method of its production and purification, vector, strain, pharmaceutical composition | |
| CN115572329B (en) | Poecilobdella manillensis gene recombinant hirudin with slower activity enhancement metabolism and preparation method thereof | |
| US8975370B2 (en) | Inhibitor proteins of a protease and use thereof | |
| RU2183214C2 (en) | Natural and recombinant thrombin inhibitors, their preparing and use | |
| JPH05213998A (en) | New polypeptide and medicinal composition containing the same as active ingredient | |
| CN115677850B (en) | Hirudo gene mutant hirudin with strong anticoagulation activity and preparation method thereof | |
| JP2798573B2 (en) | Natural polypeptide having human neutrophil elastase inhibitory activity and pharmaceutical preparation containing the same | |
| Bhakta et al. | Expression screening of bacterial libraries of recombinant alpha-1 proteinase inhibitor variants for candidates with thrombin inhibitory capacity | |
| US5231010A (en) | Recombinant aprotinin variants genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof | |
| KR100384467B1 (en) | Lumburokinase gene isolated from a earthworm and overexpression method of lumburokinase protein in yeast | |
| KR930003913B1 (en) | Method for preparation of polypeptide having thrombin inhibiting activity | |
| Inouye et al. | Replacement of all tryptophan residues in T4 bacteriophage lysozyme by tyrosine residues | |
| Zhang et al. | Expression, purification and characterization of recombinant plasminogen activator from Gloydius brevicaudus venom in Escherichia coli | |
| JPH08510903A (en) | Preparation of Recombinant Factor XA Inhibitor of Hibiscus medicinalis | |
| JPH08333400A (en) | Fused protein having antithrombogenic activity and its production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Dayong Inventor after: Sun Yan Inventor after: Wang Baochun Inventor after: Wang Daxin Inventor after: Fu Shengmiao Inventor after: Yu Bo Inventor after: Geng Lei Inventor after: Song Shaojiang Inventor after: Request for anonymity Inventor before: Wang Dayong Inventor before: Sun Yan Inventor before: Wang Baochun Inventor before: Wang Daxin Inventor before: Fu Shengmiao Inventor before: Yu Bo Inventor before: Geng Lei Inventor before: Song Shaojiang Inventor before: Request for anonymity |